Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy-Reference-Cited by-同舟云学术

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:3324-3326
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Abuasab Tareq¹,Garcia-Manero Guillermo¹,Short Nicholas²,Alvarado Yesid¹,Issa Ghayas C.¹,Islam Rubiul¹,Maiti Abhishek³,Yilmaz Musa⁴,Jain Nitin⁴,Masarova Lucia¹,Kornblau Steven M.¹,Jabbour Elias¹,Pemmaraju Naveen²,Montalban-Bravo Guillermo¹,Pierce Sherry A.¹,DiNardo Courtney D.¹,Kadia Tapan M.¹,Daver Naval¹,Konopleva Marina¹,Kantarjian Hagop⁵,Ravandi Farhad¹

Affiliation:

1. 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

2. 2Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

3. 3Department of Leukemia, The University of Texas Health Science Center At Houston, Houston, TX

4. 4Department of Leukemia, MD Anderson Cancer Center, Houston, TX

5. 5Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment;Frontiers in Pharmacology;2024-04-16

2. Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?;Journal of Clinical Medicine;2024-01-18

3. SOHO State of the Art Updates and Next Questions: Oral Therapy in Acute Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-12

4. Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024;Acta Haematologica;2023-10-31

5. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress;Expert Review of Anticancer Therapy;2023-07-20